Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540153 | 0.83 | LMNA (0.68) | SMN1; SMN2EPHX2EPHX1TP53NFKB1 | |
| SCHEMBL17410626 | 0.80 | NPC1 (0.86) | SMN1; SMN2EPHX2EPHX1RAB9ANPC1 | |
| SCHEMBL22629682 | 0.80 | CA2 (0.69) | SMN1; SMN2EPHX2EPHX1TP53RAB9A | |
| SCHEMBL14445018 | 0.80 | MEN1 (0.63) | MEN1KMT2ACA2FADS1 | |
| SCHEMBL20862664 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2EPHX2EPHX1TP53NFKB1 | |
| SCHEMBL20862516 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2EPHX2EPHX1TP53NFKB1 | |
| SCHEMBL14441194 | 0.79 | LMNA (0.70) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL11316579 | 0.78 | RAB9A (0.60) | SMN1; SMN2EPHX2EPHX1RAB9ANPC1 | |
| SCHEMBL12810968 | 0.78 | RAB9A (0.60) | SMN1; SMN2EPHX2EPHX1RAB9ANPC1 | |
| SCHEMBL31054297 | 0.78 | RAB9A (0.71) | SMN1; SMN2EPHX2EPHX1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | SMN1; SMN2 7/4885EPHX2 1185/4885EPHX1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.